+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness of basic body awareness therapy combined with lifestyle recommendations for people diagnosed with migraine. The study compares this approach with standard treatment to see its impact on migraine-related disability, sleep quality, and quality of life. Functional status will be measured by the Migraine-Related Disability Assessment Scale, sleep quality by the Jenkins Sleep Scale, and headache impact by the Headache Impact Test. Participants will be randomly assigned to one of two groups. One group will receive body awareness therapy exercises twice weekly over eight weeks in addition to standard treatment, which includes individual information sessions and educational brochures. The other group will receive only the standard treatment without the additional body awareness therapy. During the study, participants will keep a pain diary for four weeks before, during, and for four weeks after the intervention. Functional status, sleep quality, and quality of life will be assessed before starting and at the end of the eight-week program. The study includes monitoring throughout the intervention and a follow-up period, with the total duration covering the treatment and observation phases.

Age: 18Years - 55YearsAll GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are gathering real-world data to understand how Ruscus aculeatus L. works for adults with symptomatic chronic venous disease CVD classified as CEAP C1 to C6. This observational study focuses on evaluating the treatments effectiveness, safety, adherence, and impact on quality of life over 90 days. The study is conducted across multiple centers, following patients who receive Ruscus aculeatus L. as part of usual clinical care. Participants prescribed Ruscus aculeatus L. will be monitored for about 90 days without any additional study-required treatment or intervention. Treatment and care decisions are made by the patients doctors during routine visits. Clinical data including disease severity using the revised Venous Clinical Severity Score rVCSS, pain measured by the Visual Analog Scale VAS, quality of life assessed by the Chronic Venous Disease Quality of Life Questionnaire CIVIQ-20, adherence to treatment via the Visual Analog Scale for adherence VAS-U, and safety through adverse event reporting will be collected at baseline, Day 30, and Day 90. Participants will have routine clinic visits at these three time points where clinical assessments, questionnaires, and safety monitoring occur. Researchers aim to track changes in symptoms, pain, quality of life, and treatment adherence while observing any side effects. The total participation time spans approximately 90 days, allowing for comprehensive real-world observation of Ruscus aculeatus L. use in managing chronic venous disease.

Age: 18Years - 75YearsAll Genders
25 locations